Key facts
- It has raised $30.5M.
- Notable investors include Innovate UK, Creative Destruction Lab, BGF (Financial Services), University of Oxford, Oxford Science Enterprises — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Caristo Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Caristo Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Caristo Diagnostics
Developer of AI-powered technology designed to detect heart disease at its earliest stages. The company offers advanced algorithms that identify hidden heart attack risks before symptoms appear, enabling hospitals and healthcare providers to deliver early detection and personalized prevention to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2018
- Employees
- 60
- Website
- caristo.com/
- Ownership
- Privately Held (backing)
Caristo Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caristo Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caristo Diagnostics in its N-PORT filings yet. We sweep new filings monthly.